FDA: RSABE for NTID [RSABE / ABEL]

posted by Jay – India, 2018-03-26 15:31 (2303 d 15:16 ago) – Posting: # 18595
Views: 10,013

Dear all,

In one of the full replicate study of NTID the results are as per below,

Parameters   Swr    95%CI
LnCmax       0.04   0.0001
LnAUC0-t     0.07   -0.003
LnAUC0-inf   0.07   -0.004


The ABE results are as below,

Parameters   T/R    90%CI-L    90%CI-U
LnCmax       97     95         99
LnAUC0-t     99     97         101
LnAUC0-inf   99     97         101


The point estimate is near to 100 and ABE is also within 80% to 125%.

But in SABE, the Cmax criteria is more than 0 i.e. 0.0001 which leads to bioinequivalence.

So can it be scientifically justified the 95%CI of Cmax value as its very borderline to 0 and T/R shows less difference between test and reference.

Thanks

-Jay


Edit: Category and subject line changed; see also this post #1 and #2. [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,101 posts in 4,857 threads, 1,644 registered users;
83 visitors (0 registered, 83 guests [including 6 identified bots]).
Forum time: 06:48 CEST (Europe/Vienna)

One can show the following: given any rule, however “fundamental”
or “necessary” for science, there are always circumstances
when it is advisable not only to ignore the rule,
but to adopt its opposite.    Paul Feyerabend

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5